| Oral Gefitinib As Effective As Injected Docetaxel For Survival Of Patients With Non-Small-Cell Lung Cancer (Interest Study) |
| Gefitnib is as effective a second-line treatment as docetaxel for patients with non-small cell* lung cancer. The INTEREST study, published in an Article in this week's edition of The Lancet, thus establishes gefitinib as a valid treatment option for people with this condition. The study was written by Dr Edward Kim, M. D. Anderson Cancer Center, Houston, Texas, USA and colleagues.
11/21/2008
|
| Amgen, Takeda And Millennium Provide Update On Phase 3 Trial Of Motesanib In Patients With Non Small Cell Lung Cancer |
| Amgen (Nasdaq: AMGN) and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC).
11/21/2008
|
| Lung Cancer Risk In Smokers May Be Lowered By Broccoli |
| The cancer preventive properties of broccoli and other cruciferous vegetables appear to work specifically in smokers, according to data presented at the American Association for Cancer Research's Seventh Annual International Conference on Frontiers in Cancer Prevention Research.
11/19/2008
|
| Why Only Some Former Smokers Develop Lung Cancer |
| Canadian researchers are trying to answer why some smokers develop lung cancer while others remain disease free, despite similar lifestyle changes. Results were presented at the American Association for Cancer Research's Seventh Annual International Conference on Frontiers in Cancer Prevention Research. According to the Centers for Disease Control and Prevention, more people die from lung cancer than any other cancer type.
11/18/2008
|
| Extending Chemotherapy Improves Control Of Lung Cancer |
| A new Australian study has found that extending the use of chemotherapy in patients with advanced non-small cell lung cancer better controls the disease, as well as providing a modest improvement in survival. The study will be reported today (18/11) to the Clinical Oncolgoical Society of Australia Annual Scientific Meeting in Sydney.
11/18/2008
|
| First Pivotal Trials Begin For Boehringer Ingelheim's Novel Triple Angiokinase Inhibitor Vargatefâ„¢ (BIBF 1120) |
| Boehringer Ingelheim has marked a new milestone within its rapidly expanding oncology portfolio with the announcement today that the company has progressed another of its oncology compounds into pivotal phase III clinical development.
11/17/2008
|
| In Determining Overall Survival Of Lung Cancer Patients, Gender Is Key |
| Even though some combinations of gender, race and/or marital status can factor into the overall survival of nonoperative non-small cell lung cancer patients, gender is the most significant factor impacting overall survival, according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.
11/14/2008
|
| Research Demonstrating Differing Genetic Makeup Of Lung Cancer In AfricanAmerican Patients Informs Clinical Development Of EGFR Inhibitor Drugs |
| The tumors of African-American non-small cell lung cancer patients are more likely to carry a higher number of copies of the epidermal growth factor receptor (EGFR) gene and fewer mutations of EGFR itself than Caucasians according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, cosponsored by ASTRO, ASCO, IASLC and the University of Chicago.
11/14/2008
|
| Proton Therapy May Reduce Serious Side Effect Of Lung Cancer Treatment |
| Patients with locally advanced lung cancer who receive chemotherapy and proton therapy, a specialized form a radiation therapy only available in a few centers in the United States, have fewer instances of a serious side effect called bone marrow toxicity than patients who receive chemotherapy
11/14/2008
|
| Study First To Combine 2 Chemotherapies And 2 Targeted Therapies |
| The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center.
11/14/2008
|
| Overall Survival In 1st-line NSCLC Reaches 15 Months With Erbitux, Merck Serrono Informs |
| Data presented today at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology show that patients with non-small cell lung cancer (NSCLC) who were given Erbitux® (cetuximab) in addition to a standard 1st-line platinum-based chemotherapy lived significantly longer than those who received chemotherapy alone.1 This effect was more pronounced in patients treated with Erbitux who developed early acne-like rash, resulting in median overall survival of 15 months.
11/14/2008
|
| Bone Marrow Toxicity In Advanced Lung Cancer May Be Reduced By Proton Therapy And Concurrent Chemotherapy |
| Patients treated for locally advanced non-small cell lung cancer who receive chemotherapy and proton beam therapy have fewer instances of bone marrow toxicity than patients who receive the standard treatment of intensity-modulated radiation (IMRT) and concurrent chemotherapy, according to researchers from The University of Texas M. D. Anderson Cancer Center.
11/14/2008
|
| Large International Study Identifies Genetic Susceptibility To Lung Cancer |
| In a paper to be published in Nature Genetics on 2nd November, a worldwide consortium of investigators present a major breakthrough for understanding the genetic basis of lung cancer. The results are based on the largest genetic study of lung cancer ever conducted, and was organised by the International Agency for Research on Cancer (IARC, Lyon, France), the Centre National de Génotypage (CNG, Evry, France), with support from the Institut National du Cancer (Paris, France).
11/13/2008
|
| Phase 2 Study Of IMC-1121B In First-Line Treatment Of Advanced Non-Small Cell Lung Cancer Starts Patient Enrollment |
| ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed Phase 2 clinical trial of IMC-1121B in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC) has opened for patient enrollment. IMC-1121B is ImClone's proprietary fully human, IgG1 anti-vascular growth factor receptor-2 (VEGFR-2) monoclonal antibody.
11/13/2008
|
| Lung Cancer Rates Dropping But Hospitalization Rates Remain Constant, USA |
| Hospital admissions for lung cancer remained relatively stable - at roughly 150,000 a year between 1995 and 2006 - despite a steady decline in the number of Americans diagnosed with the disease, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
11/13/2008
|
